MK-1406 Injection

COMBINATION_PRODUCT2 trials

Sponsors

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Conditions

Healthy Participants

Phase 1

A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)

Active, not recruitingNCT07300085

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Healthy Participants

Start: 2025-11-08End: 2026-12-31Target: 710Updated: 2026-08-19

Phase 2

A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07)

Active, not recruitingNCT07225959

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Healthy Participants

Start: 2025-10-29End: 2027-07-31Target: 400Updated: 2026-08-20